Nearly 60 organizations and advocates representing the patient and disability communities joined PIPC's comment letter on the Centers for Medicare and Medicaid Services' (CMS) guidance implementing the Medicare Drug Price Negotiation Program.
On June 10, PIPC submitted a comment letter on the Institute for Clinical and Economic Review’s (ICER) assessment of anemia in myelodysplastic syndrome (MDS).
For over a decade, the Partnership to Improve Patient Care (PIPC) has championed centering health care on patients and people with disabilities. In this literature review, we offer the Centers for Medicare & Medicaid Services (CMS) recommendations to create a systematic engagement process that goes beyond written comment periods and ad hoc listening sessions.
On May 23, PIPC submitted a comment letter to the Colorado Prescription Drug Affordability Board (PDAB) on the Board's ongoing process for affordability reviews and establishment of upper payment limits.
PIPC submitted a letter to the Oregon Prescription Drug Affordability Board (PDAB) on the Board's ongoing affordability review activities.
On May 13, PIPC submitted a comment letter to the Maryland Prescription Drug Affordability Board (PDAB) on the Board's ongoing Cost Review Study process.
On May 7, PIPC submitted comments on the Institute for Clinical and Economic Review's (ICER) assessment of chronic obstructive pulmonary disease (COPD).
On February 6, 2024, PIPC submitted comments to the committees of jurisdiction in the Maryland House of Delegates and State Senate opposing legislation expanding the authority of the State Prescription Drug Affordability Board, and urging policymakers ban QALYs and similar measures.
|
Topics
All
Archives
July 2024
|